Reuters: Regulatory News: Bayer files suit against Lupin over plans for generic pill

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Bayer files suit against Lupin over plans for generic pill Nov 29th 2012, 17:45 FRANKFURT | Thu Nov 29, 2012 12:45pm EST FRANKFURT Nov 29 (Reuters) - German drugmaker Bayer has filed a suit in the United States against Indian generic drug maker Lupin, to prevent it from selling a version of Bayer's birth-control pill Natazia there. In the lawsuit, filed on Nov. 28, Bayer said that Lupin is preparing to bring a copy of the Natazia pill, also called Qlaira, to U.S. markets even though Bayer's U.S. patent on the pill runs through 2026. The complaint said Bayer would be entitled to an award of damages and treble damages for any commercial sale of the alleged copied product. Lupin was not immediately available for comment. Natazia is approved in the U.S. as a contraceptive and for the treatment of heavy menstrual bleeding. Birth-control is one of the most important businesses for Bayer's pharmaceuticals arm, with contraceptive sales of 1.1 billion euros in 2011. Bayer Pharma AG v Lupin Ltd. and Lupin Pharmaceuticals Inc. (Case 1:12-cv-01592-UNA) was filed with the U.S. District Court, District of Delaware.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions